A subset of myeloid dendritic cells derived from peripheral blood monocytes represented a predominant subset characterized by their potential tumor-inhibiting activity
Authors:
- 14 March 2009
- journal article
- Published by Springer Nature in In Vitro Cellular & Developmental Biology - Animal
- Vol. 45 (7) , 398-404
Abstract
Besides their role as potent antigen-presenting cells, myeloid dendritic cells (MDCs), but not plasmacytoid dendritic cells (PDCs), have been reported to have cytotoxic or cytostatic activity on some tumor cells. In this article, we analyzed the tumoristatic potential of a distinct peripheral blood monocyte-derived MDC subset which co-expressed PDC-specific marker CD123. CD123+ MDCs represented a subset of small-sized DCs and accounted for 45–60% of peripheral blood monocytes cultured with granulocyte-macrophage colony-stimulating factor and interleukine-4 (IL-4) for 7 d. They exhibited more significant antiproliferative activity toward hematological tumor cell lines of Jurkat, HL60, and myelodysplastic syndromes over-leukemia than CD123− MDCs even at a low effecter/target ratio. Pretreatment of MDC and their supernatant with TRAIL-R2:Fc significantly reduced the tumoristatic effect of CD123+ MDCs but not of CD123− MDCs and their supernatant. CD123+ MDCs expressed higher level of cytoplasmic TNF-α-related apoptosis-inducing ligand (TRAIL) than CD123− MDCs, whereas both expressed very little surface and soluble TRAIL. These results reveal that CD123+ cells represented a predominant subset of MDCs generated from peripheral blood monocytes in vitro, characterized by their potential tumoristic activity partially via cytoplasmic TRAIL.Keywords
This publication has 25 references indexed in Scilit:
- CD34+-derived CD11c+++ BDCA-1++ CD123++ DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapyCytotherapy, 2006
- Tumoricidal Potential of Native Blood Dendritic Cells: Direct Tumor Cell Killing and Activation of NK Cell-Mediated CytotoxicityThe Journal of Immunology, 2005
- Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)–producing dendritic cells: too much ado about IDO?Blood, 2005
- Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cellsCancer Science, 2005
- Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cellsImmunology Letters, 2004
- Generation of Dendritic Cells from Adherent Cells of Cord Blood by Culture with Granulocyte-Macrophage Colony-Stimulating Factor, Interleukin-4, and Tumor Necrosis Factor-αJournal of Hematotherapy & Stem Cell Research, 2000
- Reciprocal Control of T Helper Cell and Dendritic Cell DifferentiationScience, 1999
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cellsNature Medicine, 1998
- The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-LigandJournal of Experimental Medicine, 1997
- Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro.Journal of Clinical Investigation, 1990